Rekombinanter CD19 Antikörper

Produktnummer ABIN5668220

Dieses Maus Monoklonal-Antikörper erkennt spezifisch CD19 in FACS, IHC, IP, IF, Dep und in vivo. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für Rekombinanter CD19 Antikörper (ABIN5668220)

Target: CD19 (CD19 Molecule (CD19))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CD19 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunofluorescence (IF), Depletion (Dep), In vivo Studies (in vivo)

Klon: FMC63

Produktdetails anti-CD19 Antikörper

Verwendungszweck: Anti-CD19 [FMC63], Mouse IgG2a, kappa

Spezifität: This antibody is specific for human CD19, a 95 kDa protein expressed in the B-lymphocyte lineage.

Produktmerkmale:

Original Species of Ab: Mouse

Original Format of Ab: IgG2a

Aufreinigung: Protein A affinity purified

Immunogen: Human prolymphocytic leukaemia cell line JVM3.

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: FMC63 was used for four years as a CD19 antibody in various labs prior to its original publication. There, it was reported that the antibody percipitates CD19 and inhibits the binding of other CD19 antibodies to it (Zola et al., 1991, PMID: 1725979). FMC63 was used for IF and FACS of peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) (Szczepek et al., 1997, PMID: 9057669) and receptor for hyaluronan (HA)-mediated motility (RHAMM) expressing malignant B-lineage cells in myeloma (Crainie et al., 1999, PMID: 10029598). FMC63 was used for IHC and IIP of B cells in lymphocyte-filled villi and IIP of jejunal isolated lymphoid follicle, respectively, in small bowel specimens from human patients (Moghaddami et al., 1998, PMID: 9834269). FNC63 was used to induce B cell depletion in vivo (DiLillo et al., 2011, PMID: 21248259). FMC63 has been incorporated into a CD19 scFv- 41BB- CD3ζ fusion protein-encoding lentiviral vector, which was used in combination with a UCART19 cell therapy to cure high-risk CD19+ infant acute lymphoblastic leukemia (< a href="https://www.sciencedirect.com/science/article/pii/S0006497119817871" target="_blank">Qasim et al., 2017). This clone did not compete with clone HD37 (available as Ab00214) (Sakemura et al., 2023, PMID: 37879074).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu CD19

Target: CD19 (CD19 Molecule (CD19))

Andere Bezeichnung: CD19

Hintergrund: B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, Leu12, T-cell surface antigen Leu-12

UniProt: P15391

Pathways: Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung